NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of “Hold” by Brokerages

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been given an average recommendation of “Hold” by the fifteen analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $12.00.

A number of brokerages have commented on NEO. Cowen restated a “buy” rating on shares of NeoGenomics in a research report on Friday, September 12th. Leerink Partners set a $14.00 price target on shares of NeoGenomics in a report on Tuesday, October 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday, December 1st. TD Cowen lifted their target price on shares of NeoGenomics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Finally, Needham & Company LLC raised their price target on NeoGenomics from $8.00 to $14.00 and gave the company a “buy” rating in a report on Friday, August 29th.

NeoGenomics Stock Up 0.8%

NEO stock opened at $11.80 on Wednesday. NeoGenomics has a fifty-two week low of $4.72 and a fifty-two week high of $19.11. The business’s 50-day moving average is $10.45 and its two-hundred day moving average is $8.29. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.62 and a current ratio of 3.91. The company has a market cap of $1.53 billion, a price-to-earnings ratio of -13.41 and a beta of 1.60.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.The business had revenue of $187.80 million during the quarter, compared to the consensus estimate of $183.85 million. During the same period in the previous year, the company posted $0.05 EPS. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. As a group, analysts forecast that NeoGenomics will post -0.2 earnings per share for the current year.

Insiders Place Their Bets

In other NeoGenomics news, EVP Alicia C. Olivo sold 20,916 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total value of $250,992.00. Following the completion of the transaction, the executive vice president directly owned 31,083 shares in the company, valued at $372,996. This represents a 40.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 2.40% of the stock is owned by insiders.

Institutional Trading of NeoGenomics

A number of institutional investors and hedge funds have recently bought and sold shares of NEO. First Light Asset Management LLC boosted its stake in NeoGenomics by 45.0% during the third quarter. First Light Asset Management LLC now owns 9,927,269 shares of the medical research company’s stock valued at $76,639,000 after buying an additional 3,080,837 shares during the last quarter. Greenhouse Funds LLLP increased its position in shares of NeoGenomics by 57.8% during the 2nd quarter. Greenhouse Funds LLLP now owns 7,431,147 shares of the medical research company’s stock valued at $54,322,000 after purchasing an additional 2,722,823 shares during the last quarter. American Capital Management Inc. boosted its stake in NeoGenomics by 120.9% during the third quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock worth $18,105,000 after buying an additional 1,283,390 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of NeoGenomics in the second quarter valued at $6,071,000. Finally, Samjo Management LLC bought a new position in NeoGenomics during the 1st quarter valued at about $5,970,000. 98.50% of the stock is currently owned by institutional investors.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.